Comparison of lipid profiles and lipoprotein (a) levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy

Saudi Medical Journal

Volumn 27, Issue 2, 2006, Pages 174-180

  Habib, Syed S ^a   Aslam, Muhammad ^b   Naveed, Abdul K ^c   Razi, Muhammad S ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b ARMY MEDICAL COLLEGE   (Pakistan)

^c SHIFA COLLEGE OF MEDICINE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAKISTAN; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; LIPOPROTEINS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 33644514703     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Porte D Jr, Kahn SE. The key role of islet dysfunction in type II diabetes mellitus. Clin Invest Med 1995; 18: 247-254.
2. Goldberg IJ. Diabetic dyslipidemia: Causes and Consequences. J Clin Endocrinol Metab 2001; 86: 965-971.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
4. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-1774.
5. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small dense low density lipoprotein particles as a predictor of the risk of Ischemic heart disease in men. Circulation 1997; 95: 69-75.
6. Gruddy SM, Benjamin IJ, Burke GL. Diabetes and cardiovascular disease. A statement for health care professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
7. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-415.
8. Marburger C, Hambrecht R, Niebauer J, Schoeppenthau M, Scheffler E, Hauer K, et al.Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994; 73: 742-746.
9. Ernest B, Marshall LA, Barry CS, Thomas KJ, Seligsohn W. Vascular functions in Hemostasis: Lipoprotein (a) and fibrinolytic assembly. In: Williams Hematology. 6th ed. New York: McGraw-Hill; 2001. p. 1451-1470.
10. Peng YS, Juang JH. Effects of insulin therapy on non-insulin-dependent diabetics with secondary oral hypoglycemic agent failure. Changgeng Yi Xue Za Zhi 1998; 21: 271-276.
11. Porte D Jr, Kahn SE. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment-an update. Am J Med 1991; 90: 8S-14S.
12. Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord 2002; 26 (Suppl 3): S25-30.
13. Feinglos MN, Bethel MA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care 1999; 22 Suppl 3: C61-64.
14. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Med 1999; 16: 716-730.
15. Berger M, Jorgens V, Muhlhauser I. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 1999; 22 (Suppl): C71-C75.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
17. Birkeland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM: a rapid progressive disease. Results from a long-term, randomized, comparative study of insulin or sulphonylurea treatment. Diabetologia 1996; 39: 1629-1633.
18. Ruotolo G, Parlavecchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA, et al. Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 1994; 17: 6-12.
19. Romano G, Patti L, Inneli F. Insulin and sulphonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes 1997; 46: 1601-1606.
20. Mughal MA, Maheri WM, Aamir K, Jan M, Ali M. The effects of glibenclamide on serum lipids and lipoproteins in type II non insulin dependent diabetes mellitus. J Pak Med Assoc 1999; 49: 89-92.
21. Mughal MA, Maheri WM, Memon MY, Jan M, Ali M. The effects of Metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulphonylurea-treated type 2 diabetic patients with suboptimal metabolic control. J Pak Med Assoc 2000; 50: 381-385.
22. Mughal MA, Malian SA, Memon M, Malik WM, Torwani RK. Efficacy and safety of Acarbose in patients with type 2 diabetes mellitus insufficiently controlled with the diet and sulphonylureas alone. J Coll Physicians Surg Pak 2000; 10: 473-476.
23. Mughal MA, Mahar SA, Wali IAA, Maheri M, Jan M. The effects of Metformin on fasting blood glucose, blood pressure, serum lipids, lipoproteins and body weight in type of diabetes mellitus. J Coll Physicians Surg Pak 2000; 10: 405-408.
24. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
25. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
26. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
27. Graal MB, Wolffenbuttel BHR. The use of sulphonylureas in the elderly. Drugs Aging 1999; 6: 471-481.
28. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693-707.
29. Taskinen MR, Nikkila EA. Lipoprotein lipase activity of adipose tissue and skeletal muscle in insulin-deficient human diabetes. Relation to high density and very-low-density lipoproteins and response to treatment. Diabetologia 1979; 17: 351-356.
30. Stralfors P, Honnor RC. 1989 Insulin-induced dephosphorylation of hormonesensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. Eur J Biochem 1989; 182: 379-385.
31. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 1990; 265: 8854-8862.
32. Chu JW, Abbasi F, McLaughlin TL, Lamendola C, Schaaf P, Carlson TH, et al. Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycemic agents. Diabetes Obes Metab 2003; 5: 333-337.
33. Wiesli P, Spinas GA. General insulin therapy practice in type 2 diabetes mellitus. Ther Umsch 2002; 59: 402-409.
34. Haffner SM. Lipoprotein (a) and diabetes An Update. Diabetes Care 1993; 16: 835-840.
35. Chang CJ, Kao JT, Wu TJ, Lu FH, Tai TY. Serum lipids and lipoprotein (a) concentrations in Chinese NIDDM patients. Diabetes Care 1995; 18: 1191-1194.
36. Scheer WD, Boudreau DA, Cook CB. Lipoprotein (a) levels in African Americans with NIDDM. Diabetes Care 1996; 19: 1129-1134.
37. Khan MA, Baseer A. Magnitude of lipoprotein (a) in Diabetes Mellitus. J Pak Med Assoc 1998; 48: 11-13.
38. Ribault A, Durou MR, Letellier C, Wojcik F, Poirier JY, Ruelland A. Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients. Diabetes Metab 2000; 26: 107-112.
39. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein(a) levels in diabetes mellitus: Relationship to Metabolic Control. Ann Intern Med 1992; 11: 742-747.
40. Alagozlu H, Gultekin F, Candan F. Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients? Nutr Metab Cardiovasc Dis 2000; 10: 204-208.
41. Wieringa G. Lipoprotein(a): what's in a measure. Ann Clin Biochem 2000; 37: 571-580.
42. Rem C, Degree O, Boston M, Orem A, Somnos M, Allose S, et al. Plasma lipoprotein(a) levels in Turkish NIDDM patients with and without vascular diabetic complications. Acta Cardiol 1999; 54: 203-207.
43. Haffner SM, Morales PA, Stern MP, Grubek MK. Lp(a) concentration in NIDDM. Diabetes 1992; 41: 116-120.
44. Rigla M, Sanchez-Quesada JL, Ordonez-Lianos J, Part T, Caixas A, Jorba O, et al. Effect of physical exercise on lipoprotein (a) and low-density lipoprotein modifications in type I and type 2 diabetic patients. Metabolism 2000; 49: 640-647.
45. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non insulin dependent diabetes mellitus. JAMA 1990; 264: 723-726.
46. Hernandez Mijares A, Lluch I, Vizzcarra E, Martinez Triguero MI, Ascaso JF, Carmena R. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. Nutr Metab Cardiovasc Dis 2000; 10: 1-6.
47. Greco AV, Caputo S, Bertoli A, Ghirlanda G. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy. Horm Metab Res 1992; 24: 280-283.